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A long-term prospective controlled study of analgesic abuse in Belgium.
In 1991, Dubach et a! clearly demonstrated an increased risk of renal
morbidity and mortality after phenacetin abuse in middle aged working
women. We investigated the renal effects of the abuse of several kinds of
analgesics in abusers of different sex and age categories. A cohort of 200
active analgesic abusers (age range 21 to 86 years) and 200 matched
controls was followed for seven years (1984 to 1992). Subjects were visited
at home once a year for a short interview and a medical examination.
Renal function showed a significant decrease over time in controls as well
as in abusers (P < 0.001). The decrease was, however, significantly more
pronounced in abusers (P < 0.001). The development of a decreased renal
function was observed in 12 abusers and 2 controls resulting in a relative
risk of 6.1 (95% CI: 1.4 to 25.9). Subjects showing a decreased renal
function underwent a diagnostic investigation. Using validated diagnostic
criteria, analgesic nephropathy could be established in 6 Out of the 10
abusers who had a diagnostic workup, in the absence of any other form of
renal disease.
Analgesic nephropathy, a chronic progressive renal disease,
induced by the abuse of drugs containing analgesics and poten-
tially addictive substances (such as caffeine, codeine), continues to
be a serious problem in several European countries [11. A recent
investigation (end 1990) of Belgian dialysis patients, including 54
of the 55 dialysis centres, established that 15.6% of the patients
still had analgesic nephropathy [2]. Using objective criteria with
defined performance [3], the incidence of analgesic nephropathy
in chronic renal failure patients starting dialysis in 1991 to 1992
was found to be 20% in Lisbon (Portugal), 16% in Berlin
(Germany) and 15% in Linz (Austria) [ANNE study, unpublished
data]. An additional study performed in 1992 in the Czech and
Slovak Republics including 328 new ESRF patients (recruited
from 50% of the dialysis units), using the same objective diagnos-
tic criteria, showed a national incidence of 10.7% [4].
Although clinical evidence linking the abuse of analgesic mix-
tures with the development of renal failure was well documented
from the 1960's on, it was not until the 1980's that this relation was
demonstrated epidemiologically through the publication of sev-
eral case-control studies [5—8].
The most firmly based evidence of assocation is provided by the
only prospective study, reported by Dubach et al [1], who followed
a cohort of 623 working women aged 30 to 49 years with objective
evidence of the intake of phenacetin-containing analgesics and
621 age-matched controls during a 10-year follow-up period.
Urine specimens of the women investigated were analyzed for the
presence of N-acetyl-p-aminophenol (NAPAP), the main metab-
olite of phenacetin. Subjects with a positive result for NAPAP in
their urine (2 X 3 samples) at least twice were considered as
analgesic abusers. Compared to the controls, abusers showed a
more frequent raised serum creatinine (6.7% vs. 0.9%) and a low
specific gravity of urine (23% vs. 7%). The two groups did not
differ in development of bacteriuria, hematuria or proteinuria.
Based on Dubach's data, the relative risk for developing renal
failure after regular analgesic consumption of phenacetin-con-
taming products in young women could be estimated to be 8.1
(95% CI: 2.8 to 23.2) [9].
Although the strongest arguments for a causal relationship
between analgesic abuse and analgesic nephropathy came from
Dubach's study, these results only cover a small segment of the
female population and are limited to abusers of phenacetin/
paracetamol-containing analgesics. Information is still lacking
concerning the relative risk for other age and sex categories and
for abusers of different kinds of analgesics, either containing
phenacetin or not. Furthermore, for subjects developing renal
failure in the course of analgesic abuse, it is unknown whether
their renal impairment is an aggravation of a pre-existing renal
disease or is compatible with an early stage of analgesic nephrop-
athy.
This paper aims to elaborate the relative risk of renal damage
in active analgesic abusers. A prospective cohort study design is
used including active abusers of different kinds of analgesics and
matched controls who were followed during seven years. For
subjects with a decreased renal function a diagnostic workup was
performed.
Methods
A cohort of 200 active analgesic abusers and 200 matched
controls was followed for seven years. Abusers and controls were
visited at home once a year for a short interview and a medical
examination. Subjects showing a decreased renal function under-
went a diagnostic workup.
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Recruitment system
Between January 1984 and December 1985, a total of 246
healthy active analgesic abusers were referred to the research
team by family doctors (54%), pharmacists (20%), enrolled
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analgesic abusers (11%) and others (15%). Of these 246 subjects,
9 refused to participate when contacted by the team, another 19
refused the medical examination and 18 did not meet the selection
criteria retrospectively. Recruitment ended when 200 cases were
enrolled in the study. Inclusion of cases was limited to Dutch
speaking Belgians with a clear analgesic abuse defined as a daily
intake of any kind of analgesics during minimum one year and
with an overall intake of at least 1.000 units (1 unit = 1 tablet
1 suppository — I dose of powder). The presence of analgesics
was tested in blood and urine (see clinical investigations). All
abusers received a letter clearly announcing that the study aimed
to document their analgesic consumption and to investigate
different effects of analgesic abuse.
As soon as an analgesic abuser was enrolled in the study, a
matched control was randomly selected from voter lists. The pairs
of cases and controls were matched for age, sex, professional
category and living environment (level of urbanization). Controls
were excluded when they admitted an actual daily consumption of
analgesics or when they had ever used analgesics daily for a period
of more than six months or with a total intake of more than 1,000
units. Controls were also excluded retrospectively when labora-
tory evidence of analgesic consumption for a minimum of two
consecutive yearly investigations was found.
Questionnaires
At the start of the study cases and controls were interviewed at
home using a structured questionnaire dealing with the following
topics: socioeconomic characteristics, personal and familial ante-
cedents, medical and pharmaceutical consumption. The abusers
were asked more specific questions concerning their pattern of
intake, duration and amount of intake and attitude toward
analgesic consumption. Additionally, a short psychological test
was filled in by the interviewee testing neurotic lability (psycho-
neurotic complaints), neuro-somatic lability (functional com-
plaints), social extraversion and test attitude (self-defensive vs.
self-critical attitude towards completing the questionnaire). This
ABV test (Amsterdamse Biografische Vragenlijst), based on the
Eysenck personality questionnaire [10], was standardized for the
Dutch speaking population. Results were expressed in percentile
ranks according to the age and sex of the investigated subject.
During the follow-up period (year 1 to 7) a short questionnaire,
identical for cases and controls, was used, asking for the medical
antecedents, consumption of medical care and drug usage during
the last year.
For subjects deceased during the study period, a short ques-
tionnaire was sent to the family doctor in order to find out the
cause of death.
Clinical investigation
Subjects were visited at home, at the start of the study as well as
yearly during the follow-up period, by a social nurse for a short
medical investigation. Blood pressure and weight were measured
and blood and urine samples were collected. The screening tests
of the urine included a Labstix investigation of protein, blood
and glucose, the determination of creatinine and protein and a
urinary sediment analysis. The determination of creatinine in
blood and urine was based on the modified Jaffé method.
Analgesic consumption was tested in blood and urine by
checking for the presence of salicylates and paracetamol. These
two products were present separately or in combination in the
most popular analgesics, covering 90% of the Belgian sales [ii].
All determinations were performed according a colorimetric end
point method (SIGMA) based on the method of Trinder [121
and Glynn and Kendall [131.
Renal function test
Since medical examinations were performed at the subject's
home, the decision was made to evaluate renal function using the
calculated creatinine clearance according the formula of Cockroft
and Gault [14] corrected for body surface area. Since creatinine
clearance is highly influenced by age and sex, a normal distribu-
tion of creatinine clearances of the Belgian population was
established, making it possible to compare clearances of subjects
of different age and sex categories [151. Creatinine clearances
were expressed as percentile ranks according to the normal
distribution of the age and sex category of the subject. Renal
function was considered as decreased when the creatinine clear-
ance was below the third percentile rank during two consecutive
years.
Diagnostic investigation
Subjects considered as having a decreased renal function (a
creatinine clearance below the third percentile rank 2 times) were
invited for a diagnostic workup in the outpatient clinic. All
patients underwent sonography and either tomography or CT
scan. The diagnosis of analgesic nephropathy was based on renal
imaging criteria developed for end-stage renal failure patients [3],
and evaluated in patients with incipient moderate renal failure
[16] including the observation of a decrease in length of both
kidneys combined with bumpy contours or papillary calcifications.
Statistical analysis
Data analysis was performed using the BMDP statistical pack-
age for medical sciences [171. Differences between means and
proportion were investigated using the Student's t-test and Chi-
square test, respectively, combined with the 95% confidence
interval (95% CI). For the calculation of relative risk only subjects
with a normal renal function at baseline were taken into account.
Adjustment of relative risk (RR) was performed using the Man-
tel-Haenzel method for combining two-by-two tables. Data col-
lected annually (such as creatinine, proteinuria, etc.) were evalu-
ated by the analysis of variance and covariance for repeated
measurements.
Results
The cohort of 200 active analgesic abusers and 200 matched
controls was recruited in 1984 to 1985 and followed for seven
years. Evolution of the cohort is summarized in Table 1. Refusal
rate was comparable in abusers and controls, death rate was
higher in abusers. Retrospectively, six abusers and one control
were excluded from several aspects of the analysis because of a
decreased renal function from the start of the study on. These
subjects showed a corrected calculated creatinine clearance below
the third percentile rank at baseline as well as in year 1.
Additionally, one control had to be excluded because of analgesic
abuse, resulting in 192 pairs with normal renal function included
at baseline and 147 pairs ending the study with complete obser-
vations.
At the start of the study, the median age in abusers and controls
was 53 years (range 21 to 86) and 77% were female. No significant
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Table 1. Evolution of the cohort
Year
Investigated
Out of follow-up
Refused Deceased
Abusers
N
Controls
N
Complete pairs
included (N)
Abusers
N
Controls
N
Abusers
N
Controls
N
Year 0 (1984—85)
Year 1(1985—86)
Year 2 (1986—87)
Year 3 (1987—88)
Year 4 (1988—89)
Year 5 (1989—90)
Year 6 (1990—91)
Year 7 (1991—92)
200
185
183
175
170
168
167
165
200
193
193
190
186
182
181
178
192
176
174
167
159
154
152
147
—
7
1
3
1
0
0
0
—
6
0
1
3
1
0
1
8
1
5
4
2
1
2
1
0
2
1
3
1
2
Total 165 178 147 12 12 23 10
a Age and sex matched case-control pairs still in the study after exclusion of subjects with a decreased renal function at baseline
differences between both groups could be observed in body weight
(65.1 vs. 67.6 kg) and height (162.8 vs. 163.1 cm). Alcohol usage
was little higher in controls, smoking was significantly more
frequent in abusers (40 vs. 20.5%).
Compared to the general population, most analgesic abusers
had a poor socioeconomic status demonstrated by a low education
level (53% only completed elementary school), blue collar em-
ployment (40%) and a mean family income below the Belgian
median. The psychological test showed that abusers tended to
present a higher neurotic and neurosomatic lability compared to
the controls (Fig. 1). Scores on the extraversion scale and self
defensive attitude were comparable between both groups.
Abusers started their regular analgesic consumption at the
mean age of 30 (range 10 to 72). Reasons frequently given for
starting abuse were headache (54%), other physical complaints
(26%) and psychosocial problems (15%). Motivations mentioned
for sustained abuse clearly differed from the initial reasons with a
decrease in physical complaints to 47%. Fourteen percent of
abusers mentioned that they took analgesics for the stimulating
effect and 22% said that it was simply a habit.
For most abusers, the duration and the lifetime amount of
abuse clearly exceeded the minimal criteria required for inclusion,
as shown in Figure 2. Although inclusion was not limited to
abusers of analgesic mixtures, only 12 subjects took single anal-
gesics at the start of the study. However 10 out of them had
consumed analgesic mixtures in the past. Most analgesic mixtures
used contained two analgesic substances combined with poten-
tially addictive substances, mostly caffeine (Fig. 2). At the end of
the study, 10 abusers definitively stopped their analgesic consump-
tion and 15 changed over to single analgesics.
Laboratory evidence of analgesic intake in abusers, based on
determinations in serum as well as in urine, was positive (at least
5 out of 8 times) for at least one product in 82% of abusers. All
abusers who stopped their abuse during the study period showed
negative laboratory results for at least three consecutive years. In
controls, consecutive positive results (2 to 4 times) were detected
in nine cases. One control was excluded because of a clear history
of abuse admitted by the subject in year 2. The remaining eight
were found to be positive mainly for the regular use of salicylic
acid during the last part of the study.
Abusers presented a generally higher medical consumption
compared to the controls. They consulted their family doctor
more frequently, had at least one hospitalization period in 70% of
the cases and showed a higher medication usage during the study
period (Table 2). This high medical consumption was related to
the high number of medical complaints mentioned during the
yearly follow-ups. Out of the 24 complaints asked for each year,
significant differences in cause specific morbidity are summarized
in Table 3.
Analysis of the urinary parameters in complete pairs (N = 147)
was based on eight urine samples collected during eight consec-
utive years at variable points of time during the day. No significant
difference in proteirl/creatine ratio could be observed, with mean
yearly levels ranging from 41 to 136 mg/g creatinine in abusers and
from 33 to 99 mglg creatinine in controls. No differences between
the total group of abusers and controls were found and no
evolution over time was observed in the presence of sterile pyuria,
hematuria or bacteriuria, nor in the results of the sediment
analysis searching for the presence of amorph sediment, epithelial
cells, cadmium oxalate crystals and hyaline cylinders. Abusers with
a decreased renal function (Table 4) showed a higher rate of
sterile pyuria.
Renal function in abusers and controls was investigated yearly
through the determination of serum creatinine and the calculation
of creatinine clearance corrected for body surface area. Serum
creatinine levels were analyzed in all included pairs with complete
observations (N = 147). Mean serum creatinine ranged from 0.94
(± 0.29) to 1.01 (± 0.26) in the abusers and from 0.84 (± 0.15) to
0.96 (± 0.24) mgldl in controls. Analysis of variance for repeated
measures revealed a significant evolution of the serum creatinine
over time in abusers as well as in controls (P < 0.001). Comparing
the evolution in both groups, the increase in serum creatinine was
significantly more pronounced in abusers (P < 0.001).
Evolution of the creatinine clearance based on the individual
slopes of corrected calculated creatinine clearances over time for
all those preserving a normal renal function during the study
period showed a mean decrease of 0.52 ml/min/year for the
controls and 1.12 ml/min/year for the abusers (P < 0.05). In
abusers developing renal impairment during the study period(N = 12; a corrected calculated creatinine clearance below the
third percentile rank during 2 consecutive years) creatinine clear-
ance decreased of 4.14 ml/min yearly.
Clinical data for the patients considered as having renal impair-
ment are summarized in Table 4. Six abusers and one control
showed an incipient-to-moderate renal failure at baseline. Twelve
abusers and two controls developed a decreased renal function
10
10
Abusers
I I I I I I I I I
0 20 40 60 80
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during the study period showing a calculated creatinine clearance
below the third percentile rank between two and seven times. All
abusers with a decreased renal function used analgesic mixtures
containing two analgesic substances combined with potentially
addictive components (caffeine, codeine). In their case the dura-
tion and amount of analgesic consumption was comparable to the
abuse documented in the total group of abusers.
All patients with renal failure were invited for a diagnostic
workup. Six abusers and one control died without investigation.
Additionally, three subjects refused further investigations. In six
subjects the diagnosis of analgesic nephropathy was withheld
based on a decrease in length of both kidneys (sonography) and
the presence of bumpy contours on both sides or signs of papillary
necrosis demonstrated by tomography or CT scan as calcifications
on the papillary line,
In none of these analgesic nephropathy subjects a proteinuria
of more than I g/liter was observed, nor was there abnormal
findings in their sediment analysis.
For calculation of the relative risk (RR) 194 abusers and 198
controls showing a normal renal function at baseline were taken
into account (Table 5). A decreased renal function, defined as a
corrected calculated creatinine clearance below the third percen-
tile rank at least twice, was observed in 12 abusers and 2 controls,
resulting in a RR of 6.1. Adjustment for smoking had no influence
on this risk calculation.
For mortality an increased RR of 2.2 (95% CI: 1.0 to 4.6) was
observed. After adjustment for smoking, the RR decreased to 1.8
and was not significant. Causes of death in abusers were of
cardiovascular origin (N = 8), cancer (N = 6), renal failure (N =
2) and others (N = 3). Two of the cancer patients in the abusers
group developed an urothelial tumour. In the controls cardiovas-
cular mortality accounted for six deaths, and cancer was the cause
of death in the remaining three subjects.
Discussion
A prospective cohort study, proceeding from cause to effect,
provides the most firmly based evidence of assocation between the
exposure to a toxic agent and the development of a disease. It has
the distinct advantage of permitting uniformity in observation and
a direct estimation of the magnitude of the risk. In the study
presented, a sixfold increased risk for developing renal impair-
ment was found after ingestion of different kinds of analgesic
mixtures in a sample of abusers of different sex and age categories
compared to their matched controls.
A B
Controls
60
50
.2 30
0
:3
ci)z
Mean (95%) Cl)
74.3 (70.8-77.8)
r
54.6 (49.8-59.5)
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0
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4
0
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20
80.5 (77.8-83.2)
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Fig. 1. Psychological characteristics of (A,N = 161) abusers and (B; N = 136) controls
expressed in percentile ranks according to sex and
age. (Eysenck personality questionnaire,
standardized for the Dutch speaking
population) [10].
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This risk rate is comparable with the observation made in the
prospective study of Dubach, where in young females a relative
risk of 8.1 was found after the ingestion of phenacetin containing
analgesics [I]. Lower but strikingly comparable estimations of this
risk were derived from the case-control studies recently published.
Taking into account all kinds of analgesics consumed, odds ratios
of 2.4 to 2.8 to 2.9 were reported by Pommer, Sandier and
Morlans, respectively. Although the methodology used for selec-
tion of cases (from newly diagnosed analgesic nephropathy pa-
tients to ESRF patients) and controls (from population based to
hospitalized) and the definition of abuse handled (from 15
units/month for 30 days to daily for one year) varied considerably
in these studies, comparable odds ratios were obtained [6—8].
However, increasing the minimum intake to more than 60 units
per month for at least five years, Pommer et at [71 reported an
increased odds ratio of 4.8, comparable with the observations of
Dubach's study and the presented study.
Neither the presented study nor any other prospective study in
this field will be able to demonstrate the causal relationship
between analgesic abuse and the development of renal disease.
Products used
Perdolan
Mann
Witte Kruis
Dolviran
Optalidon
Saridon
Lonarid
Other mixtures
Single analgesics
Components
Analgesic Other
o2(na) 0
c - c >' ( 0(CC
11* p
11* IRu.HI .Ru.
Year 0
N .%
41 21
38 19
25 1318 9
12 663
5 2
11 5
12 6
32 16
200 100
Year 7
N %
36 23
14 9
12 8
12
9 6.
5 3
4 3.
13 8
27 17
23 15
155 100
10
Two or more
* Antipyrine
+ Salipyrine
-
** Carbromal
Stopped abuse
Out of follow-up 35
200
Distribution of the duration of abuse Distribution of the amount of abuse
Year 0 25
Mean (95% Cl):
Year 0
20
20.3 (18.5-22.1)
15
Mean (95% Cl):
36.1 (31 .4-40.8)
10
20
15
10
5
0
Number of years Number of units, thousands
Fig. 2. Description of the abuse including products used at baseline and at the end of the study period, composition (1983) of the main products used and
duration and total amount of abuse at baseline.
5
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Table 2. Medical consumption during study period
Abusers Controls
(N 147) (N = 147)
Mean Mean
(95% CI) (95% CI) P value
Consultation family 12.8 (10.4—15.3) 3.8 (3.1—4.6) <0.001
doctor (mean!
year)
Hospitalization (%) 70.1 (63—78) 51.7 (44—60) 0.01
Medication
No daily drug 1.4 (0.2—5) 14.3 (9—20) <0.001
usage" %
Number of drugs 2.3 (2.1—2.6) 1.0 (0.8—1.1) <0.001
used daily
Kind of drugs
used %
Cardiovascular 66.0 (58—74) 39.5 (32—47) <0.00 1
Antacids 27.9 (21—35) 11.6 (6—17} <0.001
Sedatives 71.4 (64—79) 23.8 (17—31) <0.001
Antidepressives 39.5 (32—47) 9.5 (5—16) <0.001
Anti-migraine 25.9 (19—33) 3.4 (1—8) <0.001
Narcotic 22.4 (16—29) 0.0 (0—2) <0.001
analgesics
NSAID 51.0 (43—59) 23.1 (16—30) <0.001
"analgesics excluded
For obvious ethical reasons, it is impossible to observe a cohort of
abusers from the start of the abuse on. Therefore, differentiation
between cause and effect remains difficult in the study presented.
Are abusers higher medical consumers and do they have an
increased morbidity as a result of their abuse, or did they start
their analgesic consumption because they had increased physical
complaints? Is hypertension either a causative agent or a result of
excessive analgesic consumption?
The number of abusers who developed renal impairment during
the study period of seven years was 6.2%. Dubach found a similar
result with 6.7% of young female abusers showing an increased
serum creatinine twice over a 10 year observation period [11.
Furthermore, only a small number of the abuser population
develops ESRF. After a follow-up of 20 years, Dubach reported
that 16 out of 576 cases with complete observations died from
renal causes, and four cases additionally developed ESRF and
received chronic dialysis treatment [1]. Derived from his data, the
absolute risk for developing ESRF attributable to analgesic abuse
can be calculated to be 1.7!1000/year.
In Belgium, this absolute risk rate could be confirmed in a
completely different study design. A 1984 population survey based
on a random sample of 833 subjects in three areas of the northern
part of Belgium showed that 2.1% of the population abused
analgesics [11]. The 1990 incidence of analgesic nephropathy in
the dialysis population of the same areas was 0.033!1.000 [3]. The
absolute risk for developing ESRF in the context of analgesic
abuse was 1.6!1.000/year [18].
Moreover, analgesic nephropathy is a disease with a long
latency. In the present study, a decreased renal function was
observed after regular analgesic consumption for periods ranging
from 5 to 56 years. Similar results were obtained in a Scottish
study of analgesic nephropathy patients (creatinine clearance
below 75 ml!min) where the duration of ingestion varied from 4 to
45 years (average 20 years) [191 and in West Berlin where the
average period of abuse until ESRF occurred was found to be 21
12 years [20].
Table 3. Differences in morbidity during study perioda in included pairs
with complete observation
Abusers
W=147
Controls
N=147 RR
adjusted
Complaints % P value for smoking 95% CI
Depression" 52.4 27.9 <0.001 2.6 1.6—4.3
Hypertension" 49.7 28.6 <0.001 3.4 2.0—5.8
Gastric 43.5 17.7 <0.001 3.4 1.9—5.9
Diarrhea 32.0 9.5 <0.001 5.3 2.7—10.4
Anemia" 21.1 6.1 <0.001 3.9 1.8—8.8
Asthma 18.4 8.8 <0.025 2.4 1.2—5.0
"Based on the questionnaire, performed at yearly intervals, concerning
24 complaints during the preceding year. Percentages are based on the
number of subjects reporting this complaint at least one time.
"Medically treated
Although large differences in age distribution existed between
the population studied by Dubach and the presented study,
comparable risk ratios for mortality were obtained. In Dubach's
study, the relative risk of death in the total study group as
compared with the control group was 2.2 (CI 1.5 to 3.3). We
obtained a relative risk for mortality of 1.8 which was no longer
significant after adjustment for smoking (CI 0.8 to 4.2).
A diagnostic investigation was performed in 11 subjects out of
the 21 who showed a decreased renal function either at baseline or
during the study period. The remaining subjects died or refused to
come to the outpatient clinic for a diagnostic workup (Table 4).
Analgesic nephropathy was diagnosed in six subjects using diag-
nostic criteria with well defined performance showing predictive
values in excess of 90% [3]. Although these criteria were devel-
oped for ESRF patients starting renal replacement therapy, in a
case series (N = 53) of analgesic abusers with a serum creatinine
between 1.5 and 4 mg!dl we recently found that, even in this early
stage of renal failure, especially the detection of papillary calcifi-
cations showed a high sensitivity of 92% [16]. None of the
analgesic nephropathy patients had a proteinuria of more than
1 g!liter or clinical signs of other renal diseases, suggesting that in
these cases abuse was the direct cause for developing renal
impairment rather than it causes the aggravation of a pre-existing
renal disease.
In contrast with Dubach, who recruited his subjects among
female workers in industrial plants around Basel, dividing them in
cases and controls according to their laboratory evidence of
analgesic consumption, we recruited on a voluntary base from the
general population. It is clear that a random sample from the
unregistered population of abusers cannot be taken. Two major
arguments, however, demonstrate the representation of our sam-
ple of abusers. First, we compared the social characteristics of the
participants and refusals as noted on the registration forms used
by pharmacists and general practitioners for recruitment. No
significant differences could be observed between those who
consented and those who refused to participate in their age and
sex distribution nor in their socioeconomic status. Secondly, the
duration and amount of analgesic intake of the abusers compared
to chronic renal failure patients with documented analgesic
nephropathy showed an identical pattern of abuse in both groups
[3].
As described previously, subjects were completely informed
about the aims of the study and those who were willing to
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Table 4. Description of patients with decreased renal rfunctiona
Ab
N=
N
users
194
%
Cant
N=
N
rols
198
%
RR
adjusted
for smoking 95% CI
Decreased renal 12 6.2 2 1.0 6.1 1.4—25.9
functionC
Mortality 19 9.8 9 4.5 1.8 0.8—4.2
Relative risk calculations were based on 194 abusers and 198 controls
with normal renal function at baseline. Refusal rate during the study
period was in both groups N = 12.
Calculated creatinine clearance corrected for body surface area at
least twice below the 3th percentile rank (according sex and age) of a
Belgian population sample.
participate were also willing to talk about their abuse. In contrast
with analgesic nephropathy patients, where it has repeatedly been
documented that they tend to deny their analgesic consumption
[211, we obtained more reliable results since the consistency of our
information, obtained at yearly intervals, was remarkably high.
The "open" interview situation enabled a clear documentation
of the abuse showing that abusers prefer analgesic mixtures and
that sustained abuse is no longer related to a physical complaint
for most of them. It is clearly demonstrated that the addition of
substances like caffeine, codeine and barbiturates can create a
psychological dependence on these drugs [19].
All abusers with renal impairment had a long-standing history
of abuse of analgesic mixtures containing two analgesic substances
combined with potentially addictive compounds. Evidence is
growing that these kinds of analgesic products have the highest
nephrotoxic potency [2]. While, until the 1980s, most of these
mixtures contained phenacetin, this substance has disappeared
from the market in Belgium as well as in the other West-
European countries. However, the prevalence of analgesic ne-
phropathy remains high in Western Europe, and the number of
patients with clearly documented analgesic nephropathy who
never consumed analgesics containing phenacetin is growing [221.
The example of Australia, confronted with an identical situation
at the end of the 1970s, shows that only through an efficient
legislation can a clear decrease in the occurrence of analgesic
nephropathy be expected [23].
As shown on Table 2, abusers presented a generally higher
medical consumption compared to the controls. They used more
different kinds of medication daily. Their consumption of seda-
tives, anti-depressives, anti-migraine, narcotic analgesics and
NSAID's was particularly high. Since the risk of NSAID use for
the development of chronic renal failure is still a matter of debate,
NSAID usage was controlled for confounding. In any case,
NSAID did not contribute to the observed risk for developing
renal failure.
Although we and others [19, 201 were able to identify the
segment of the population at risk of developing this addictive
behavior (women with low socioeconomic status and neurotic
lability), we do not believe that informative preventive campaigns
focused on the population at risk will help limit the abuse. Ninety
percent of abusers admitted at the start of the study that they
knew about the possible health risks related to the abuse of
analgesics. Moreover, each time an abuser showed a creatinine
clearance below the third percentile rank or other signs of renal
dysfunction (bacteriuria, hematuria), the subject was sent to the
family doctor and we informed him about the possible relation
with extensive analgesic consumption. Despite these warnings,
CN
Age
at start Sex
Ccr mi/nun Renal diagnosis
(cause of death)
Description of abuse
n < p3 mm—max Productsb Duration years
Abusers
At start 17 46 F 8 10—21 Analgesic Nephropathy Veganine-Dolviran 30
19 75 M 1 22—22 C year 1 (bronchus CA) Mann 28
94 86 F 3 15—28 C year 3 (cardiovasc.) Witte Kruis 51
109 82 F 3 12—17 C year 3 (renal failure) Witte Kruis 56
170 72 F 1 19—19 C year 1 (cardiovasc.) Mann 57
176 61 F 8 23—31 Analgesic nephropathy Veganine-Dolviran 32
During 5 70 F 5 22—93 Diabetic nephropathy Mann 39
13 32 M 2 57—115 Urolithiasis Perdolan 11
80 80 F 2 26—45 C year 6 (cardiovasc.) Wjtte Kruis-Perdolan 56
81 78 M 3 22—33 year 6 (renal failure) Saridon 5
85 52 F 4 36—61 Analgesic nephropathy Mann 12
86 50 F 5 33—54 Analgesic nephropathy Mann-Perdolan 22
95 52 F 2 4 1—73 Investigation refused Witte Kruis 22
134 52 F 5 37—73 Analgesic nephropathy Mann-Lonarid 24
137 78 F 2 26—49 Cause unspecified Dolviran-Troc 38
220 34 F 7 31—69 Analgesic nephropathy Mann-Perdolan 18
221 61 F 3 34—78 Vascular nephropathy Mann 31
239 39 M 2 63—1 15 Investigation refused Optalidon-Perdolan 20
Controls
At start 108 82 M 1 21—21 C year 1 (cardiovasc.) — —
During 42 39 M 2 60—99 Urolithiasis — —
81 78 M 5 28—37 Investigation refused — —
CN is code number.
Corrected creatinine clearance at least twice below the third percentile
h Products abused before Start of study
C deceased
Table 5. Relative risk
rank (<p3) according to the normal distribution
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only 10 abusers definitively stopped their abuse and 15 changed
over to single analgesics. Moreover, of all abusers who developed
renal impairment during the study period, only 2 stopped their
regular analgesic consumption.
In conclusion, this prospective study showed that the abuse of
analgesic mixtures forms a sixfold increased risk for the develop-
ment of renal impairment in subjects of different sex and age
categories. The renal impairment was found to be compatible with
the diagnosis of analgesic nephropathy in six abusers (out of the
10 investigated) in the absence of other forms of renal disease. All
the cases developing renal impairment abused analgesic mixtures
of varying composition suggesting once more that only by limiting
the availability of all kinds of analgesic mixtures, a decrease in the
occurrence of this disease can be obtained.
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